Antiangiogenic gene therapy of cancer: recent developments - Test2 - elhamkhani - TriplyDB

Antiangiogenic gene therapy of cancer: recent developments

Antiangiogenic gene therapy of cancer: recent developments

http://www.wikidata.org/entity/Q24803786

about

Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension KSHV-Mediated Angiogenesis in Tumor Progression Anti-angiogenic gene therapy in the treatment of malignant gliomas A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs.Imaging hemodynamics.A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors.Suppression of peritoneal tumorigenesis by placenta-derived mesenchymal stem cells expressing endostatin on colorectal cancer.Vascular damage and anti-angiogenic effects of tumor vessel-targeted adenovirus-mediated herpes simplex virus thymidine kinase gene.Regulation of vascular endothelial cell polarization and migration by Hsp70/Hsp90-organizing protein Anti-angiogenic potential of an ethanol extract of Annona atemoya seeds in vitro and in vivo.Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies.Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma Antiangiogenic therapy for glioma.Regulators of apoptosis: suitable targets for immune therapy of cancer.Delivery of antiangiogenic agents for cancer gene therapy.Gene therapy for gastric cancer: is it promising?Gene therapy vector design strategies for the treatment of cancer.Cancer gene therapy targeting angiogenesis: an updated review.Adenoviral gene therapy in gastric cancer: a review.Antiangiogenic strategies in medulloblastoma: reality or mystery.Is cancer gene therapy an empty suit?Therapeutic cancer vaccines in combination with conventional therapy.Emerging biotechnological strategies for non-viral antiangiogenic gene therapy.Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.Update on oncolytic viral therapy - targeting angiogenesis Vastatin, an Endogenous Antiangiogenesis Polypeptide That Is Lost in Hepatocellular Carcinoma, Effectively Inhibits Tumor Metastasis.Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.In vitro targeted gene electrotransfer to endothelial cells with plasmid DNA containing human endothelin-1 promoter.Tumor vasculature-targeted delivery of tumor necrosis factor-alpha.The effects of systemic and intratumoral interleukin-12 treatment in C6 rat glioma model.Sendai viroplexes for epidermal growth factor receptor-directed delivery of interleukin-12 and salmosin genes to cancer cells.Adeno-associated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer.Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma.Multimodal Assessment of Mesenchymal Stem Cell Therapy for Diabetic Vascular Complications.Immunomodulatory glc/man-directed Dolichos lablab lectin (DLL) evokes anti-tumour response in vivo by counteracting angiogenic gene expressions.

P2860

Q24807061-99ACF1F6-1DD3-447E-AD48-96BE4BB61EB7 Q26742030-F140E603-1564-4343-AE2C-F738E7350B22 Q26866276-2D279F9A-19B4-454A-86FD-D77E992646A7 Q27335560-65E7020C-64D6-49DC-B399-351BFF614CF8 Q30439974-4E0F951F-1332-4D5D-BB58-1A8966497C9D Q33576606-A71C5310-BD8D-49A9-9F56-6F19789240F4 Q33760569-6AF03ACD-1AD5-438D-BDDC-D88A8A3A774B Q33843839-1CA48D4C-0F6F-4E7E-B5BF-8ECE8E8122B8 Q34224929-D634C927-930E-4F6C-AEDD-AE4BF07FC4E1 Q34257507-6BFE6DBA-6A42-411B-9CD5-4A09BA08297F Q34267340-76C5199C-541B-45F9-BC28-40009F475535 Q34498600-5339CF4C-C5FB-4563-AFD2-6D1545F170F4 Q34499002-B03C832E-FF26-47ED-8751-91D899919D62 Q34849516-33B7469C-0178-409F-BBBB-E96ED16524AA Q34987834-DC67EA30-4877-4F75-8859-E7F9DC1D488B Q36101999-70EE9FC6-24A2-4F71-B15F-F1B8E4B0F233 Q36111911-8CFB4395-6802-44EA-BD6D-F1833995A8FE Q36200143-E3672423-6A69-4C02-9927-7EE82B4B5367 Q36401504-8858EE69-D700-4855-A18A-25F9E3E7BF8B Q36429492-C308DB71-E1AE-4B25-85D2-288BB6C5BE1D Q36655133-2478368F-E565-4689-AB45-A729767E3278 Q37054346-BDAD691F-339F-4328-AD90-44D16F1C8144 Q37143958-4757C751-21AE-4C06-950B-4B4344208335 Q37564361-8CE1D0F4-A6BE-413B-8651-1C41B12DB4CA Q37771267-DABE4183-6B25-4C32-ACF4-3E6542218EF8 Q38034448-F95282DF-DCE3-44FA-81FF-4A14FE315E04 Q38107203-086A1011-626B-4553-93D2-43EB3DEAFB6F Q38128561-D91732DC-C212-4E55-800D-55670BD29B55 Q38787495-93667A39-CA53-40E4-8099-EFFFCEF739C0 Q38964255-ACF44054-01E1-444E-A985-229788A68839 Q39154948-071C63BA-DA39-4C75-8D23-42050D8F9D9A Q39904196-ACC1DD01-77B4-417C-9F52-D9F3A48B44FE Q39924722-F2F94058-ED1B-4110-88BD-DDC332425702 Q40748569-4F44006C-C9B8-40F1-97D8-BC185AB77A82 Q45378265-FB903A9A-D591-4E0A-9916-737AC5F3B95A Q45857995-317DFAA3-9017-471E-9ECD-F42DC41C7ADB Q47112812-3E754175-0406-4E6F-93C9-2B1C23F9187A Q48153977-40EB4ABE-C656-48FB-83E7-0659CB233064

P2860

Antiangiogenic gene therapy of cancer: recent developments

http://www.wikidata.org/entity/Q24803786

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Antiangiogenic gene therapy of cancer: recent developments

@ast

Antiangiogenic gene therapy of cancer: recent developments

@en

Antiangiogenic gene therapy of cancer: recent developments

@nl

type

label

Antiangiogenic gene therapy of cancer: recent developments

@ast

Antiangiogenic gene therapy of cancer: recent developments

@en

Antiangiogenic gene therapy of cancer: recent developments

@nl

prefLabel

Antiangiogenic gene therapy of cancer: recent developments

@ast

Antiangiogenic gene therapy of cancer: recent developments

@en

Antiangiogenic gene therapy of cancer: recent developments

@nl

P1433

Q24803786-3AF58073-6623-4DA8-B92F-E04E8C19137D

P1476

Q24803786-5ED9DCFE-D470-4B10-99B1-3BC02DCEB2E9

P2093

Q24803786-7C8C2BAF-E026-494A-9FFC-CB20F3D9E445

Q24803786-C1213B11-41C2-4FFB-8FB0-F477344C1670

P2860

Q24803786-011CFD88-64C2-4E22-A101-52A3638B2115

Q24803786-01CF60FE-8F50-4BA4-8755-316EF9C4A8C0

Q24803786-02BAB32C-DDFD-479A-A3F3-FA6F3341BBE2

Q24803786-03B2FF1A-75B6-4CC2-B63C-0A6A6EFC994B

Q24803786-04165F3D-DF4B-4EC9-B6C9-79E9038FD831

Q24803786-043FD53D-1D1B-4475-A378-EC650BC05EEC

Q24803786-055C77F9-E005-415A-ADB9-46994DDE44EB

Q24803786-065AC618-41D7-4FC0-811E-3472AB802B0B

Q24803786-07A5E6CA-3B07-4441-91C5-DD38BA5D994A

Q24803786-083E8A6B-6ED8-4456-949A-0DEEF1E8B6EF

P2888

Q24803786-1B3A03AF-852C-4264-AF53-8DD9511ACDF0

P304

Q24803786-7FE3CE44-DDD0-4191-854C-03954CAEE9C4

P31

Q24803786-F9AA387E-E004-4091-A9C6-75FCFDB60809

P3181

Q24803786-C4EA9E46-DC79-4919-A200-3874F6A162D1

P356

Q24803786-EB67839D-1A9E-4BFA-9F9A-E30184123506

P433

Q24803786-B09D1B24-5BDA-4314-BB5E-1A5FEB357BFD

P478

Q24803786-960CD461-1FF4-4D33-99DF-446654E4D406

P50

Q24803786-1E0FFF81-BA06-4963-AF32-107897408F16

P577

Q24803786-2A440B60-86B5-4EF6-B101-79C35A867643

P5875

Q24803786-BED734C5-A053-4EA5-8024-CC9F1B35FE01

P6179

Q24803786-D477F632-D24C-44AF-9FBE-CC3C69317CB3

P698

Q24803786-0C093184-5A45-4CC3-86D7-A3031928E621

P921

Q24803786-0F8A0AAD-DD2A-4070-B7B7-BE24A4D45E1A

P932

Q24803786-C8A159C3-E250-42E4-B148-E206757E14ED

P3181

P356

P1433

Journal of Translational Medicine

P1476

Antiangiogenic gene therapy of cancer: recent developments

@en

P2093

Anita Tandle

http://www.w3.org/2001/XMLSchema#string

Steven K Libutti

http://www.w3.org/2001/XMLSchema#string

P2860

Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth

Distinct antitumor properties of a type IV collagen domain derived from basement membrane

Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties

Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides

Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins

Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF

Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells

Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

Angiostatic steroids. Method of discovery and mechanism of action

P2888

P304

22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4475437

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1479-5876-2-22

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8489557

http://www.w3.org/2001/XMLSchema#string

P6179

1050335737

http://www.w3.org/2001/XMLSchema#string

P698

15219236

http://www.w3.org/2001/XMLSchema#string

P921

P932

455695

http://www.w3.org/2001/XMLSchema#string